EX-99.1 2 ef20035948_ex99-1.htm EXHIBIT I
Exhibit I

JOINT FILING AGREEMENT
 
This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of shares of Common Stock, $0.001 par value per share, of BridgeBio Pharma, Inc. is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below that is named as a reporting person in such filing in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
 
Dated: September 17, 2024
 
KKR GENETIC DISORDER L.P.
 
By: KKR Genetic Disorder GP LLC, its general partner
   
 
By:
/s/ Christopher Lee
 
Name:
Christopher Lee
 
Title:
Assistant Secretary
     
 
KKR GENETIC DISORDER GP LLC
   
 
By:
/s/ Christopher Lee
 
Name:
Christopher Lee
 
Title:
Assistant Secretary
     
 
KKR GROUP PARTNERSHIP L.P.
 
By: KKR Group Holdings Corp., its general partner
   
 
By:
/s/ Christopher Lee
 
Name:
Christopher Lee
 
Title:
Secretary
     
 
KKR GROUP HOLDINGS CORP.
   
 
By:
/s/ Christopher Lee
 
Name:
Christopher Lee
 
Title:
Secretary
     
 
KKR GROUP CO. INC.
   
 
By:
/s/ Christopher Lee
 
Name:
Christopher Lee
 
Title:
Secretary
     
 
KKR & CO. INC.
   
 
By:
/s/ Christopher Lee
 
Name:
Christopher Lee
 
Title:
Secretary
 
 
KKR MANAGEMENT LLP
   
 
By:
/s/ Christopher Lee
 
Name:
Christopher Lee
 
Title:
Assistant Secretary

 
HENRY R. KRAVIS
   
 
By:
/s/ Christopher Lee
 
Name:
Christopher Lee
 
Title:
Attorney-in-fact
     
 
GEORGE R. ROBERTS
   
 
By:
/s/ Christopher Lee
 
Name:
Christopher Lee
 
Title:
Attorney-in-fact


2